Theodore Togliatti, MD
Interventional Pain Medicine · Mansfield, OHNPI 1275755993
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,430 and has fallen 81.4% since, to $267 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in OH, where the typical reported total is $5,193.
Across 337 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$852
- Pfizer$533
- AbbVie$516
- Amgen$359
- Scilex Pharmaceuticals Inc.$341
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,197100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 71 | $1,020 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 68 | $852 |
| Pfizer | 44 | $533 |
| AbbVie(2 entities) | 32 | $516 |
| Amgen(2 entities) | 16 | $359 |
| Scilex Pharmaceuticals Inc. | 27 | $341 |
| Boston Scientific | 11 | $283 |
| Biodelivery Sciences International, Inc. | 19 | $255 |
| Teva Pharmaceuticals USA, Inc. | 12 | $186 |
| Nevro Corp. | 4 | $126 |
| Si-bone, Inc. | 3 | $113 |
| Captiva Spine Inc | 1 | $107 |
| Biohaven Pharmaceuticals, Inc. | 4 | $76 |
| MDD US Operations, LLC | 4 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| Zyla Life Sciences, Inc. | 3 | $45 |
| Forte Bio-pharma LLC | 2 | $31 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
| Assertio Therapeutics, Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $15 |
| Bioventus LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,197 in reported general payments places this provider in the 50th percentile of 67 interventional pain medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 12 | $28,158 |
| Xtampza ErOxycodone Myristate | 44 | $22,915 |
| BelbucaBuprenorphine Hcl | 27 | $21,854 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 812 | $15,394 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $15,128 |
| MovantikNaloxegol Oxalate | 25 | $13,631 |
| OxycontinOxycodone Hcl | 13 | $5,564 |
| Fentanyl | 70 | $5,062 |
| Pregabalin | 210 | $4,798 |
| Gabapentin | 333 | $3,559 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 210 | $2,802 |
| Celecoxib | 97 | $2,708 |
| Morphine Sulfate ErMorphine Sulfate | 149 | $2,663 |
| Cyclobenzaprine Hcl | 250 | $2,065 |
| Oxycodone Hcl | 130 | $1,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $1,020 | $44,76971 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $852 | $28,15812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 67 interventional pain medicine providers in Ohio.
Other interventional pain medicine in Mansfield
- James WolfeMansfield$2K
- Gladstone McDowellColumbus$660K
- Humam AkbikFairfield$116K
- Sara NashiCincinnati$116K
- Jaudat MahmoodKent$97K
- Omar AliSpringfield$67K
- Dustin ReynoldsWesterville$61K
- James OttingToledo$47K
- Mark MalinowskiChillicothe$39K
- David WalegaColumbus$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.